In 2024, IBSA Pharma OÜ had revenue of 45.5 thousand EUR and profit of 2 thousand EUR. Beneficial owners: Arturo-Pino Giuseppe Antonio Licenziati.
| year | 2024Latest | 2023 |
|---|---|---|
Revenue | 45,5k € +569.7% | 6,8k € |
Profit | 2k € +496.5% | 340 € |
Assets | - | - |
Liabilities | - | - |
Equity | 27,4k € +8.0% | 25,3k € |
Employees | - | - |
Overall rating | A87/100 |
Financial health | 95/100 |
Credit history | 70/100 |
Legal history | 100/100 |
Business activity | 85/100 |
| Overall risk | Low |
No risk flags | |
Possible tax debts | |
Positive profit | |
Regular report filing | |
| Name, surname | Birth date | Position | Representation rights | Registered | |
|---|---|---|---|---|---|
| - | Board member | - | |||
| - | Board member | - | |||
| - | Board member | - | |||
| - | Procurator | - |
IBSA Pharma OÜ is located at Harju maakond, Tallinn, Kesklinna linnaosa, Pärnu mnt 139e/2, 11317.
In 2024, IBSA Pharma OÜ had revenue of 45 540 EUR and profit of 2028 EUR. Compared to previous year, revenue increased by 569.7%. View full financial report →
The beneficial owners of IBSA Pharma OÜ are Arturo-Pino Giuseppe Antonio Licenziati. View ownership details →
No, IBSA Pharma OÜ does not have an active VAT number and is not registered as a VAT payer.
IBSA Pharma OÜ was founded on September 28, 2022. The company has been operating for 4 years.
| Indicator | Value | Rank | Comparison | |
|---|---|---|---|---|
Company age | 4 years | 1453 - 1457 | 35% | |
Net revenue | 45 540,00 € | 810 - 814 | 64% | |
Profit | 2028,00 € | 1112 - 1116 | 50% | |
Equity | 27 368,00 € | 763 - 767 | 64% | |
Liquidity | 4.92 | - | 90% | |
Profitability | 4.5% | - | 10% | |
Registered capital | 25 000,00 € | - | 90% |
Annual financial report for 2024.
Annual financial report for 2023.
Registered in the Estonian business register.
| Name, surname | Shares | Ownership rights | |
|---|---|---|---|
| IBSA Holding SA | - | 100.00% |
| Name, surname | Nationality | Birth date | |
|---|---|---|---|
| Arturo-Pino Giuseppe Antonio Licenziati | CH | - |